US Stock Market Movement: Replimune Group Surges on October 29th; TUDRIQEV Prescription, Rating Upgrade, and Oncolytic Immunotherapy

Replimune Group Soars on October 29: Analysis

Keywords: TUDRIQEV prescription, rating upgrade, oncolytic immunotherapy

1. On October 28, the company released its fiscal 2027 Q2 results and provided an update on the commercial progress of TUDRIQEV: the company's main business is innovative oncolytic immunotherapy. TUDRIQEV was first used for advanced melanoma patients on October 6, with prescriptions issued by over 15 institutions. The company has engaged with more than 70% of the first batch of 200 key institutions, and has over a year's inventory; the drug has been commercially available in the US since October 1 and is used in combination with nivolumab for certain advanced melanoma cases.

2. On October 28, the company reported a diluted loss per share of $0.54 for fiscal 2027 Q2, narrowing from $0.90 in the same period last year; net loss was $57.1 million, down from $83.1 million a year ago; as of September 30, cash and cash equivalents totaled $307.8 million.

3. On October 29, several institutions updated their ratings, with target prices ranging from $19 to $31; Leerink Partners raised its target price from $19 to $31 and maintained its “outperform” rating.

(Disclaimer: This content is collected and summarized using AI technology based on public information and is for reference only. It does not constitute investment advice.)